Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers

Cancer Cell

Volumn 31, Issue 4, 2017, Pages 476-485

  Majzner, Robbie G ^a   Heitzeneder, Sabine ^a   Mackall, Crystal L ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

adoptive T cell therapy; checkpoint inhibitor; chimeric antigen receptor; immunotherapy; monoclonal antibody; pediatric oncology

Indexed keywords

BISPECIFIC ANTIBODY; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; BLINATUMOMAB; CD19 MOLECULE, HUMAN; CH14.18 MONOCLONAL ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CHILD; CHILDHOOD CANCER; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SYNTHETIC BIOLOGY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MUTATION; NEOPLASMS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; HUMANS; IMMUNOTHERAPY; MUTATION; NEOPLASMS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN; RECOMBINANT PROTEINS;

EID: 85016510938     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.03.002     Document Type: Review

References (120)

1. Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33 (2015), 1688–1696.
2. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Borresen-Dale, A.L., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
3. Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., Schuster, S.J., Millenson, M.M., Cattry, D., Freeman, G.J., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372 (2015), 311–319.
4. Anurathapan, U., Chan, R.C., Hindi, H.F., Mucharla, R., Bajgain, P., Hayes, B.C., Fisher, W.E., Heslop, H.E., Rooney, C.M., Brenner, M.K., et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol. Ther. 22 (2014), 623–633.
5. Balar, A.V., Galsky, M.D., Rosenberg, J.E., Powles, T., Petrylak, D.P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J.L., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389 (2017), 67–76.
6. Bhoj, V.G., Arhontoulis, D., Wertheim, G., Capobianchi, J., Callahan, C.A., Ellebrecht, C.T., Obstfeld, A.E., Lacey, S.F., Melenhorst, J.J., Nazimuddin, F., et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood 128 (2016), 360–370.
7. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 1627–1639.
8. Bouffet, E., Larouche, V., Campbell, B.B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34 (2016), 2206–2211.
9. Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
10. Brentjens, R.J., Riviere, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118 (2011), 4817–4828.
11. Brown, C.E., Alizadeh, D., Starr, R., Weng, L., Wagner, J.R., Naranjo, A., Ostberg, J.R., Blanchard, M.S., Kilpatrick, J., Simpson, J., et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375 (2016), 2561–2569.
12. Burgess, M., Crowley, J., Reinke, D., Riedel, R., George, S., Movva, S., Van Tine, B.A., Davis, L.E., Schuetze, S., Hu, J., et al. (2015). SARC 028: a phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. Paper presented at: American Society of Clinical Oncology.
13. Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E.S., Ittmann, M.M., Marchetti, D., Dotti, G., Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 21 (2015), 524–529.
14. Curran, E., Corrales, L., Kline, J., Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front Oncol., 5, 2015, 83.
15. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 2014, 224ra225.
16. De Henau, O., Rausch, M., Winkler, D., Campesato, L.F., Liu, C., Cymerman, D.H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 539 (2016), 443–447.
17. Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359 (1992), 162–165.
18. Duffner, P.K., Armstrong, F.D., Chen, L., Helton, K.J., Brecher, M.L., Bell, B., Chauvenet, A.R., Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A report from the Children's Oncology Group. J. Pediatr. Hematol. Oncol. 36 (2014), 8–15.
19. Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S.E., Krailo, M., Devidas, M., Barkauskas, D.A., Siegal, G.P., et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J. Clin. Oncol. 30 (2012), 2545–2551.
20. Eleveld, T.F., Oldridge, D.A., Bernard, V., Koster, J., Daage, L.C., Diskin, S.J., Schild, L., Bentahar, N.B., Bellini, A., Chicard, M., et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat. Genet. 47 (2015), 864–871.
21. Findlay, J.M., Castro-Giner, F., Makino, S., Rayner, E., Kartsonaki, C., Cross, W., Kovac, M., Ulahannan, D., Palles, C., Gillies, R.S., et al. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat. Commun., 7, 2016, 11111.
22. Frei, E., Freireich, E.J., Gehan, E., Pinkel, D., Holland, J.F., Selawry, O., Haurani, F., Spurr, C.L., Hayes, D.M., James, G.W., et al. Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Blood 18 (1961), 431–454.
23. Frobisher, C., Gurung, P.M., Leiper, A., Reulen, R.C., Winter, D.L., Taylor, A.J., Lancashire, E.R., Woodhouse, C.R., Hawkins, M.M., Risk of bladder tumours after childhood cancer: the British Childhood Cancer Survivor Study. BJU Int. 106 (2010), 1060–1069.
24. Galili, N., Davis, R.J., Fredericks, W.J., Mukhopadhyay, S., Rauscher, F.J. 3rd, Emanuel, B.S., Rovera, G., Barr, F.G., Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 5 (1993), 230–235.
25. Galloway, T.J., Indelicato, D.J., Amdur, R.J., Swanson, E.L., Smith, A.A., Marcus, R.B. Jr., Second tumors in pediatric patients treated with radiotherapy to the central nervous system. Am. J. Clin. Oncol. 35 (2012), 279–283.
26. Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L.A., Finney, O., Smithers, H., Jensen, M.C., Riddell, S.R., Maloney, D.G., et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127 (2016), 2406–2410.
27. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 2018–2028.
28. Gill, S., Tasian, S.K., Ruella, M., Shestova, O., Li, Y., Porter, D.L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S.A., et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123 (2014), 2343–2354.
29. Gonzalez-Gugel, E., Saxena, M., Bhardwaj, N., Modulation of innate immunity in the tumor microenvironment. Cancer Immunol. Immunother. 65 (2016), 1261–1268.
30. Gore, L., Locatelli, F., Zugmaier, G., Zwaan, C.M., Bhojwani, D., Handgretinger, R., Bader, P., O'Brien, M.M., Trippett, T.M., Brethon, B., et al. Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood, 124, 2014 Abstract 3703.
31. Grady-Leopardi, E.F., Schwab, M., Ablin, A.R., Rosenau, W., Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: relationship to clinical outcome. Cancer Res. 46 (1986), 3196–3199.
32. Green, M.R., Monti, S., Rodig, S.J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T.R., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116 (2010), 3268–3277.
33. Haso, W., Lee, D.W., Shah, N.N., Stetler-Stevenson, M., Yuan, C.M., Pastan, I.H., Dimitrov, D.S., Morgan, R.A., FitzGerald, D.J., Barrett, D.M., et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121 (2013), 1165–1174.
34. Haymaker, C.L., Kim, D., Uemura, M., Vence, L.M., Phillip, A., McQuail, N., Brown, P.D., Fernandez, I., Hudgens, C.W., Creasy, C., et al. Metastatic melanoma patient had complete response with clonal expansion after whole brain radiation and PD-1 blockade. Cancer Immunol. Res. 5 (2017), 100–105.
35. Heczey A., L.C.U., Savoldo B., Dakhova O., Grilley B.J., Gee A., Dotti GP, Heslop H.E., Rooney C.M., Brenner M.K. (2016). Autologous T cells expressing a GD2 specific chimeric antigen receptor with CD28 and OX40 costimulatory endodomains for children with neuroblastoma. Paper presented at: Advances in Neuroblastoma Research Congress.
36. Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S.A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K.K., et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J. Clin. Invest. 126 (2016), 3036–3052.
37. Herter-Sprie, G.S., Koyama, S., Korideck, H., Hai, J., Deng, J., Li, Y.Y., Buczkowski, K.A., Grant, A.K., Ullas, S., Rhee, K., et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight, 1, 2016, e87415.
38. Hiniker, S.M., Chen, D.S., Reddy, S., Chang, D.T., Jones, J.C., Mollick, J.A., Swetter, S.M., Knox, S.J., A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl. Oncol. 5 (2012), 404–407.
39. Hu, Y., Wu, Z., Luo, Y., Shi, J., Yu, J., Pu, C., Liang, Z., Wei, G., Cui, Q., Sun, J., et al. Potent anti-leukemia activities of chimeric antigen receptor modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia. Clin. Cancer Res., 2016, 10.1158/1078-0432.CCR-16-1799.
40. Jacoby, E., Nguyen, S.M., Fountaine, T.J., Welp, K., Gryder, B., Qin, H., Yang, Y., Chien, C.D., Seif, A.E., Lei, H., et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun., 7, 2016, 12320.
41. Jha, P., Suri, V., Singh, G., Jha, P., Purkait, S., Pathak, P., Sharma, V., Sharma, M.C., Suri, A., Gupta, D., et al. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagn. Mol. Pathol. 20 (2011), 225–232.
42. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.A., Lanier, B.J., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116 (2010), 4099–4102.
43. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., Stetler-Stevenson, M., Phan, G.Q., Hughes, M.S., Sherry, R.M., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 (2012), 2709–2720.
44. Koller, K.M., Mackley, H.B., Liu, J., Wagner, H., Talamo, G., Schell, T.D., Pameijer, C., Neves, R.I., Anderson, B., Kokolus, K.M., et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol. Ther. 18 (2016), 36–42.
45. Kumai, T., Kobayashi, H., Harabuchi, Y., Celis, E., Peptide vaccines in cancer-old concept revisited. Curr. Opin. Immunol. 45 (2016), 1–7.
46. Lagmay, J.P., Krailo, M.D., Dang, H., Kim, A., Hawkins, D.S., Beaty, O. 3rd, Widemann, B.C., Zwerdling, T., Bomgaars, L., Langevin, A.M., et al. Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through children's cancer group, pediatric oncology group, and children's oncology group: learning from the past to move forward. J. Clin. Oncol. 34 (2016), 3031–3038.
47. Lancashire, E.R., Frobisher, C., Reulen, R.C., Winter, D.L., Glaser, A., Hawkins, M.M., Educational attainment among adult survivors of childhood cancer in Great Britain: a population-based cohort study. J. Natl. Cancer Inst. 102 (2010), 254–270.
48. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
49. Lee, D.W., Gardner, R., Porter, D.L., Louis, C.U., Ahmed, N., Jensen, M., Grupp, S.A., Mackall, C.L., Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 (2014), 188–195.
50. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385 (2015), 517–528.
51. Lim, S.H., Levy, R., Translational medicine in action: anti-CD20 therapy in lymphoma. J. Immunol. 193 (2014), 1519–1524.
52. Liniker, E., Menzies, A.M., Kong, B.Y., Cooper, A., Ramanujam, S., Lo, S., Kefford, R.F., Fogarty, G.B., Guminski, A., Wang, T.W., et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology, 5, 2016, e1214788.
53. Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W.A., Xu, H., Peng, H., Fu, Y.X., Xu, M.M., CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21 (2015), 1209–1215.
54. Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., Smith, J.P., Walker, A.J., Kohler, M.E., Venkateshwara, V.R., et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21 (2015), 581–590.
55. Long, A.H., Highfill, S.L., Cui, Y., Smith, J.P., Walker, A.J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M.G., Orentas, R.J., et al. Reduction of MDSCs with All-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4 (2016), 869–880.
56. Louis, C.U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G.D., Rossig, C., Russell, H.V., Diouf, O., Liu, E., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118 (2011), 6050–6056.
57. Majzner, R.G., Walker, A.J., Murgai, M., Zhang, L., Long, A.H., Wanhainen, K.M., Orentas, R.J., Mackall, C.L. (2016). Chimeric antigen receptor T-cell therapy against anaplastic lymphoma kinase (ALK) is limited by target antigen density and CAR surface expression. Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016. 10.1158/1538-7445.AM2016-2648.
58. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
59. McGranahan, N., Furness, A.J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
60. Merchant, M.S., Bernstein, D., Amoako, M., Baird, K., Fleisher, T.A., Morre, M., Steinberg, S.M., Sabatino, M., Stroncek, D.F., Venkatasan, A.M., et al. Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin. Cancer Res. 22 (2016), 3182–3191.
61. Merchant, M.S., Wright, M., Baird, K., Wexler, L.H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J.D., et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin. Cancer Res. 22 (2016), 1364–1370.
62. Michot, J.M., Mazeron, R., Dercle, L., Ammari, S., Canova, C., Marabelle, A., Rose, S., Rubin, E., Deutsch, E., Soria, J.C., et al. Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. Eur. J. Cancer 66 (2016), 91–94.
63. Moran, A.E., Kovacsovics-Bankowski, M., Weinberg, A.D., The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr. Opin. Immunol. 25 (2013), 230–237.
64. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., Rosenberg, S.A., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18 (2010), 843–851.
65. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., Tykodi, S.S., Sosman, J.A., Procopio, G., Plimack, E.R., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373 (2015), 1803–1813.
66. Mouw, K.W., Cleary, J.M., Reardon, B., Pike, J., Braunstein, L.Z., Kim, J., Amin-Mansour, A., Miao, D., Damish, A., Chin, J., et al. Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. Clin. Cancer Res., 2016, 10.1158/1078-0432.CCR-16-2017.
67. Moynihan, K.D., Opel, C.F., Szeto, G.L., Tzeng, A., Zhu, E.F., Engreitz, J.M., Williams, R.T., Rakhra, K., Zhang, M.H., Rothschilds, A.M., et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22 (2016), 1402–1410.
68. Oberlin, O., Rey, A., Sanchez de Toledo, J., Martelli, H., Jenney, M.E., Scopinaro, M., Bergeron, C., Merks, J.H., Bouvet, N., Ellershaw, C., et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J. Clin. Oncol. 30 (2012), 2457–2465.
69. Pappo, A.S., Patel, S.R., Crowley, J., Reinke, D.K., Kuenkele, K.P., Chawla, S.P., Toner, G.C., Maki, R.G., Meyers, P.A., Chugh, R., et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J. Clin. Oncol. 29 (2011), 4541–4547.
70. Parsons, D.W., Li, M., Zhang, X., Jones, S., Leary, R.J., Lin, J.C., Boca, S.M., Carter, H., Samayoa, J., Bettegowda, C., et al. The genetic landscape of the childhood cancer medulloblastoma. Science 331 (2011), 435–439.
71. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365 (2011), 725–733.
72. Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366 (2012), 925–931.
73. Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., Linette, G.P., Meyer, N., Giguere, J.K., Agarwala, S.S., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372 (2015), 2006–2017.
74. Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H.A., Petrylak, D.P., Teng, S.L., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
75. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., Huls, M.H., Liu, E., Gee, A.P., Mei, Z., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14 (2008), 1264–1270.
76. Qin, H., Haso, W., Nguyen, S.M., Fry, T.J., Preclinical development of bispecific chimeric antigen receptor targeting both CD19 and CD22. Blood, 126, 2015, 4427.
77. Qin, H., Cho, M., Haso, W., Zhang, L., Tasian, S.K., Oo, H.Z., Negri, G.L., Lin, Y., Zou, J., Mallon, B.S., et al. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood 126 (2015), 629–639.
78. Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fulop, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375 (2016), 1823–1833.
79. Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M., Wansley, E.K., Camphausen, K., Luiten, R.M., de Ru, A.H., Neijssen, J., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203 (2006), 1259–1271.
80. Reulen, R.C., Winter, D.L., Frobisher, C., Lancashire, E.R., Stiller, C.A., Jenney, M.E., Skinner, R., Stevens, M.C., Hawkins, M.M., British Childhood Cancer Survivor Study Steering Group, Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304 (2010), 172–179.
81. Ribas, A., Hamid, O., Daud, A., Hodi, F.S., Wolchok, J.D., Kefford, R., Joshua, A.M., Patnaik, A., Hwu, W.J., Weber, J.S., et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315 (2016), 1600–1609.
82. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
83. Rizvi, N.A., Mazieres, J., Planchard, D., Stinchcombe, T.E., Dy, G.K., Antonia, S.J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16 (2015), 257–265.
84. Roberts, K.G., Morin, R.D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.C., Payne-Turner, D., Churchman, M.L., Harvey, R.C., et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22 (2012), 153–166.
85. Roberts, K.G., Li, Y., Payne-Turner, D., Harvey, R.C., Yang, Y.L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371 (2014), 1005–1015.
86. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372 (2015), 2521–2532.
87. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., Dawson, N., O'Donnell, P.H., Balmanoukian, A., Loriot, Y., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
88. Ruella, M., Barrett, D.M., Kenderian, S.S., Shestova, O., Hofmann, T.J., Perazzelli, J., Klichinsky, M., Aikawa, V., Nazimuddin, F., Kozlowski, M., et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J. Clin. Invest. 126 (2016), 3814–3826.
89. Savoldo, B., Ramos, C.A., Liu, E., Mims, M.P., Keating, M.J., Carrum, G., Kamble, R.T., Bollard, C.M., Gee, A.P., Mei, Z., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121 (2011), 1822–1826.
90. Schlegel, P., Lang, P., Zugmaier, G., Ebinger, M., Kreyenberg, H., Witte, K.E., Feucht, J., Pfeiffer, M., Teltschik, H.M., Kyzirakos, C., et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 99 (2014), 1212–1219.
91. Schramm, A., Koster, J., Assenov, Y., Althoff, K., Peifer, M., Mahlow, E., Odersky, A., Beisser, D., Ernst, C., Henssen, A.G., et al. Mutational dynamics between primary and relapse neuroblastomas. Nat. Genet. 47 (2015), 872–877.
92. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
93. Schwab, M., Alitalo, K., Klempnauer, K.H., Varmus, H.E., Bishop, J.M., Gilbert, F., Brodeur, G., Goldstein, M., Trent, J., Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305 (1983), 245–248.
94. Shah, N.N., Stetler-Stevenson, M., Yuan, C.M., Shalabi, H., Yates, B., Delbrook, C., Zhang, L., Lee, D.W., Stroncek, D., Mackall, C.L., et al. Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood, 128, 2016, 650.
95. Shankar, A.G., Ashley, S., Craft, A.W., Pinkerton, C.R., Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med. Pediatr. Oncol. 40 (2003), 141–147.
96. Shlien, A., Campbell, B.B., de Borja, R., Alexandrov, L.B., Merico, D., Wedge, D., Van Loo, P., Tarpey, P.S., Coupland, P., Behjati, S., et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat. Genet. 47 (2015), 257–262.
97. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001), 783–792.
98. Smith, M.A., Seibel, N.L., Altekruse, S.F., Ries, L.A., Melbert, D.L., O'Leary, M., Smith, F.O., Reaman, G.H., Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J. Clin. Oncol. 28 (2010), 2625–2634.
99. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
100. Sockolosky, J.T., Dougan, M., Ingram, J.R., Ho, C.C., Kauke, M.J., Almo, S.C., Ploegh, H.L., Garcia, K.C., Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc. Natl. Acad. Sci. USA 113 (2016), E2646–E2654.
101. Sotillo, E., Barrett, D.M., Black, K.L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M.R., et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5 (2015), 1282–1295.
102. Spranger, S., Luke, J.J., Bao, R., Zha, Y., Hernandez, K.M., Li, Y., Gajewski, A.P., Andrade, J., Gajewski, T.F., Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc. Natl. Acad. Sci. USA 113 (2016), E7759–E7768.
103. Stamell, E.F., Wolchok, J.D., Gnjatic, S., Lee, N.Y., Brownell, I., The abscopal effect associated with a systemic anti-melanoma immune response. Int. J. Radiat. Oncol. Biol. Phys. 85 (2013), 293–295.
104. Swart, M., Verbrugge, I., Beltman, J.B., Combination approaches with immune-checkpoint blockade in cancer therapy. Front Oncol., 6, 2016, 233.
105. Taraseviciute, A., Kean, L., and Jensen, M. (2016). Creation of the first non-human primate model that faithfully recapitulates chimeric antigen receptor (CAR) T cell-mediated cytokine release syndrome (CRS) and neurologic toxicity following B cell-directed CAR-T cell therapy. Paper presented at: Blood.
106. Taylor, A.J., Little, M.P., Winter, D.L., Sugden, E., Ellison, D.W., Stiller, C.A., Stovall, M., Frobisher, C., Lancashire, E.R., Reulen, R.C., et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J. Clin. Oncol. 28 (2010), 5287–5293.
107. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
108. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
109. Topp, M.S., Kufer, P., Gokbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.A., Raff, T., Viardot, A., Schmid, M., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29 (2011), 2493–2498.
110. Topp, M.S., Gokbuget, N., Stein, A.S., Zugmaier, G., O'Brien, S., Bargou, R.C., Dombret, H., Fielding, A.K., Heffner, L., Larson, R.A., et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16 (2015), 57–66.
111. Turatti, F., Figini, M., Balladore, E., Alberti, P., Casalini, P., Marks, J.D., Canevari, S., Mezzanzanica, D., Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J. Immunother. 30 (2007), 684–693.
112. Turtle, C.J., Hanafi, L.A., Berger, C., Gooley, T.A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T.M., et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126 (2016), 2123–2138.
113. Turtle, C.J., Riddell, S.R., Maloney, D.G., CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies. Clin. Pharmacol. Ther. 100 (2016), 252–258.
114. Versteege, I., Sevenet, N., Lange, J., Rousseau-Merck, M.F., Ambros, P., Handgretinger, R., Aurias, A., Delattre, O., Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394 (1998), 203–206.
115. Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N.I., Miller, W.H. Jr., Lao, C.D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16 (2015), 375–384.
116. Weigel, B., Malempati, S., Reid, J.M., Voss, S.D., Cho, S.Y., Chen, H.X., Krailo, M., Villaluna, D., Adamson, P.C., Blaney, S.M., Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr. Blood Cancer 61 (2014), 452–456.
117. Weijtens, M.E., Hart, E.H., Bolhuis, R.L., Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther. 7 (2000), 35–42.
118. Wu, G., Broniscer, A., McEachron, T.A., Lu, C., Paugh, B.S., Becksfort, J., Qu, C., Ding, L., Huether, R., Parker, M., et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44 (2012), 251–253.
119. Yankelevich, M., Kondadasula, S.V., Thakur, A., Buck, S., Cheung, N.K., Lum, L.G., Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr. Blood Cancer 59 (2012), 1198–1205.
120. Yu, A.L., Gilman, A.L., Ozkaynak, M.F., London, W.B., Kreissman, S.G., Chen, H.X., Smith, M., Anderson, B., Villablanca, J.G., Matthay, K.K., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363 (2010), 1324–1334.